{"id":23757,"date":"2022-09-12T12:26:05","date_gmt":"2022-09-12T10:26:05","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=23757"},"modified":"2022-11-03T11:18:07","modified_gmt":"2022-11-03T10:18:07","slug":"success-leads-to-launch-of-next-phase","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/","title":{"rendered":"Success leads to launch of next phase"},"content":{"rendered":"\n

Biotech company Biosergen has had such good results with the first four groups of subjects in their Phase 1 study that they are now launching the next part of the study, which involves “multiple dose” as opposed to “single dose” so far in the study. This is a quarter ahead of schedule and supports the investment case of Biosergen and the SEK 60M rights issue.<\/strong><\/p>\n\n\n\n

Biosergen: Ticker BIOSGN | Price: 4,1 | Market Cap.: SEK 115M | YTD price development: -23%<\/em><\/p>\n\n\n\n

Biosergen <\/a><\/strong>is a biotech company listed on Nasdaq First North Sweden in June 2021. The company is developing an innovative drug to treat fungal infections that kill 1.5 million people annually – in both industrialised and third world countries.<\/p>\n\n\n\n

The company’s BSG005 agent has demonstrated significant safety data and potency advantages over existing products developed in the 1950s-70s. BSG005 is in clinical phase I (the first of three phases of development towards the market), from which positive data have emerged. The first of several drugs is expected to be on the market in 2026\/27.<\/p>\n\n\n\n

View Kapital Partner’s investment case on Biosergen here<\/a><\/mark><\/strong><\/p>\n\n\n\n

No harmful effect on liver or kidneys<\/strong><\/p>\n\n\n\n

One of the two major benefits of Bioserg’s treatment for aggressive (deadly) fungal infections is that patients do not suffer kidney damage, a major side effect of existing treatment. Preliminary results of the Phase 1 study have shown that subjects have not experienced any liver or kidney side effects, so the multiple dose part of the study is already underway.<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech company Biosergen has had such good results with the first four groups of subjects in their Phase 1 study that they are now launching the next part of the study, which involves “multiple dose” as opposed to “single dose” so far in the study. This is a quarter ahead of schedule and supports the […]<\/p>\n","protected":false},"author":11,"featured_media":23516,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[151,165],"tags":[],"class_list":["post-23757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-cases","category-investment-cases"],"acf":[],"yoast_head":"\nSuccess leads to launch of next phase | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Success leads to launch of next phase | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Biotech company Biosergen has had such good results with the first four groups of subjects in their Phase 1 study that they are now launching the next part of the study, which involves “multiple dose” as opposed to “single dose” so far in the study. This is a quarter ahead of schedule and supports the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-12T10:26:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-03T10:18:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"840\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Success leads to launch of next phase\",\"datePublished\":\"2022-09-12T10:26:05+00:00\",\"dateModified\":\"2022-11-03T10:18:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/\"},\"wordCount\":252,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg\",\"articleSection\":[\"Company cases\",\"Investment cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/\",\"name\":\"Success leads to launch of next phase | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg\",\"datePublished\":\"2022-09-12T10:26:05+00:00\",\"dateModified\":\"2022-11-03T10:18:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg\",\"width\":840,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Company cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/company-cases\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Success leads to launch of next phase\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Success leads to launch of next phase | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/","og_locale":"en_US","og_type":"article","og_title":"Success leads to launch of next phase | Kapital Partner A\/S","og_description":"Biotech company Biosergen has had such good results with the first four groups of subjects in their Phase 1 study that they are now launching the next part of the study, which involves “multiple dose” as opposed to “single dose” so far in the study. This is a quarter ahead of schedule and supports the […]","og_url":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2022-09-12T10:26:05+00:00","article_modified_time":"2022-11-03T10:18:07+00:00","og_image":[{"width":840,"height":600,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Success leads to launch of next phase","datePublished":"2022-09-12T10:26:05+00:00","dateModified":"2022-11-03T10:18:07+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/"},"wordCount":252,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg","articleSection":["Company cases","Investment cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/","url":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/","name":"Success leads to launch of next phase | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg","datePublished":"2022-09-12T10:26:05+00:00","dateModified":"2022-11-03T10:18:07+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/09\/Biosergen-update.jpg","width":840,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/success-leads-to-launch-of-next-phase\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"Company cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/company-cases\/"},{"@type":"ListItem","position":4,"name":"Success leads to launch of next phase"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/23757"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=23757"}],"version-history":[{"count":4,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/23757\/revisions"}],"predecessor-version":[{"id":23762,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/23757\/revisions\/23762"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/23516"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=23757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=23757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=23757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}